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The purpose of this study was to model the metallic port in breast tissue expanders
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planning system (TPS). The density of the model was determined by comparing TPS
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and to improve the accuracy of dose calculations in a commercial photon treatment
calculations and ion chamber (IC) measurements. The model was further validated
and compared with two widely used clinical models by using a simpliﬁed anthropomorphic phantom and thermoluminescent dosimeters (TLD) measurements. Dose
perturbations and target coverage for a single postmastectomy radiotherapy (PMRT)
patient were also evaluated. The dimensions of the metallic port model were determined to be 1.75 cm in diameter and 5 mm in thickness. The density of the port
was adjusted to be 7.5 g/cm3 which minimized the differences between IC measurements and TPS calculations. Using the simpliﬁed anthropomorphic phantom, we
found the TPS calculated point doses based on the new model were in agreement
with TLD measurements within 5.0% and were more accurate than doses calculated
based on the clinical models. Based on the photon treatment plans for a real
patient, we found that the metallic port has a negligible dosimetric impact on chest
wall, while the port introduced signiﬁcant dose shadow in skin area. The current
clinical port models either overestimate or underestimate the attenuation from the
metallic port, and the dose perturbation depends on the plan and the model in a
complex way. TPS calculations based on our model of the metallic port showed
good agreement with measurements for all cases. This new model could improve
the accuracy of dose calculations for PMRT patients who have temporary tissue
expanders implanted during radiotherapy and could potentially reduce the risk of
complications after the treatment.
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1 | INTRODUCTION

accuracy of the model; Trombetta et al.20 initially reported that no

More and more postmastectomy patients have immediate breast

pair of 6 MV photon beams delivered to a breast phantom contain-

reconstructions mainly for cosmetic reasons.1–7 A temporary tis-

ing a metallic port, but later drew a conﬂicting conclusion in a sep-

sue expander, which usually includes a high-density magnetic

arate paper21 that the metallic port must be taken into account in

injection port, offers many advantages including relative simplic-

the dose calculations; Strang et al.22 used TLD measurements and

ity, low morbidity, and good aesthetic results, over other types

concluded that radiation doses around the tissue expander were

signiﬁcant change in dose distributions was found for an opposed

3,6

American Society of Plastic Surgeons

unaltered; Srivastava et al.23 conducted measurements in a water

reported that there were 74,694 breast reconstructions using tis-

phantom using a small ion chamber (IC) and concluded that dose

sue expander/implant in 2014 in the US and the number kept

perturbation caused by metallic port in photon beams was 5%~20%

increasing.8

and this perturbation could not be predicted by TPS; Zabihzadeh

of breast reconstructions.

Many patients will receive postmastectomy radiotherapy (PMRT)

et al.24 used MC simulation and found a dose enhancement about

with the temporary tissue expander present, while the tissue expan-

15% in front of the port and a dose reduction of about 10% at

der could negatively impact the effectiveness of PMRT and increase

5 cm under the port; Gee et al.25 used radiochromic ﬁlms as

9,10

the risk of complications.

Some physicians felt the reconstruc6

in vivo dosimeter and found an average 7% dose reduction to skin

tions challenged their ability to deliver effective radiotherapy. It has

surface in a sample of PMRT patients with the tissue expander

also been reported that failures in the breast reconstruction and

present during radiotherapy.

complication rates were signiﬁcantly higher for patients who

One of the reasons for these contradictory ﬁndings is that most

received PMRT with the temporary tissue expanders than patients

of the current TPSs are not calibrated or validated for the high-

who received PMRT with permanent implants11 or autologous tissue

density metallic port in the tissue expander. Considering TPS is an

12,13

reconstruction.

essential step among the whole radiotherapy procedure, it is critical

Previous literature about the effect of the tissue expander con-

to calibrate it to generate accurate treatment plans for patients

taining the high-density metallic injection port on dose distribution

with tissue expanders. The modeling of the metallic port in the cur-

was conﬂicting and controversial: Moni et al.14 used thermolumi-

rent TPS may not be able to accurately calculate the dosimetry

nescent dosimeters (TLD) and found no signiﬁcant component of

impact introduced by the high-density materials, particularly in the

scatter dose around the metallic port, no increased dose at the sur-

areas near these materials.16,18 Thompson and Morgan15 manually

face of the expander, and no excess dose due to the metallic port

assigned a bulk density of 7.9 g/cm3 to the implant in TMS TPS

15

used diode dosimetry in

(Nucletron, Veenendaal, the Netherlands) and concluded this kind

a water phantom and reported the attenuation of up to 30% of

of modeling was ineffective; Chen et al.18 used a series of phantom

local dose for a single beam, and treatment target could be under-

and ﬁlm measurements to ﬁnd an electron density relative to water

dosed by approximately 10% in clinical situations using tangential

of 11.8 for the metallic port in an open ﬁeld photon beam in

parallel opposed beams. They also concluded the modeling of this

Eclipse TPS (Varian Medical Systems, Palo Alto, CA, USA). How-

dose perturbation in treatment planning systems (TPS) was inade-

ever, this value did not yield good agreement between measure-

quate; Damast et al.16 reported that the potential dose perturbation

ments and TPS calculations for both 6 and 18 MV photon beams;

of the tissue expander could be as much as 22% for a single 6 MV

Trombetta et al.20 assigned the density of the metallic port in the

beam and 16% for a single 15 MV beam based on ex vivo ﬁlm

Eclipse TPS to be 5 g/cm3 which is the highest available value in

dosimetry. The in vivo ﬁlm measurement one side at a time for

the system. Except for one abstract19 in which the details and

one PMRT patient treated with 15 MV beams concurred with

accuracy of the model were not provided, none of the previous

ex vivo results, while TLD measurements for six patients treated

studies created and validated a model of the metallic port with

with 15 MV beams showed smaller dose variation (86%~101% of

generic dimensions and density that can be applied to different

prescription dose). They recommended using 15 MV photons with

beam energies, neither did they investigate the impact of the

in the expander; Thompson and Morgan

17

used

metallic port on any advanced techniques like intensity-modulated

Monte Carlo (MC) simulation and found 7% to 13% dose reduction

radiotherapy (IMRT) or volumetric-modulated arc therapy (VMAT),

with the expander in place for two 6 MV tangential photon beams,

while these techniques have been used to treat postmastectomy

and around 6% dose reduction for 18 MV beams; Chen et al.18

patients.26

compensating bolus to treat patients; Chatzigiannis et al.

reported that tissue expanders with metal ports will increase dose

In this study, we aim to model the metallic port in a commercial

heterogeneity and reduce dose coverage signiﬁcantly for patients

TPS (Pinnacle version 9.8 TPS, Philips Healthcare, Fitchburg, WI,

treated with 6 MV or 18 MV opposed tangent photon ﬁelds; Shar-

USA) based on radiological properties of the port. We optimized our

abi et al. reported in an abstract19 5%~20% dose attenuation due

model until TPS calculations matched measurement results, and vali-

to the metallic port and claimed a nondeformable implant model of

dated the model using a simpliﬁed anthropomorphic phantom. We

the port was created based on manufacture speciﬁcations, but they

also compared the new model with two widely used clinical models

did not show the details of the model or validate the dosimetric

in the phantom and for a patient case.

YOON

|

ET AL.

2 | MATERIAL AND METHODS
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metallic port was put on the surface of a solid water slab and the distance from the water surface to the slab surface was 5 cm. The IC

2.1 | Modeling of the metallic port

was placed directly under the metallic port to measure the dose

A metallic port (Fig. 1) was separated from the MAGNA-SITEâ injec-

attenuation through the metallic port and the position of the IC varied

tion site in the Natrelleâ 133 Tissue Expander (ALLERGAN, Santa
Barbara, CA) for this study. The metallic port consists of a magnetic
disk (Nd2Fe14B; Neodymium magnet, nominal density = 7.4 g/cm3)
with physical dimensions of 2.1 cm diameter and 3.5 mm thickness,
and a Titanium shell casing (nominal density = 4.2 g/cm3) with physical dimensions of 3.5 cm diameter and 0.4 mm thickness.
To model the dimensions of the metallic port in the Pinnacle version 9.8 TPS, we measured cross-sectional proﬁles of transmitted
beams through the metallic port by ﬁlm instead of using its physical
dimensions. A piece of Gafchromic EBT3 ﬁlm (Ashland, Bridgewater,
NJ, USA) was placed on the bottom of a water tank at 100 sourceto-axis distance (SAD) without any back-scattering phantom to
reduce scatter contribution. The metallic port was placed on the ﬁlm
surface parallel or perpendicular to the radiation beam and the water
tank was ﬁlled with 5 cm depth of water. A 6 MV photon beam with
10 9 10 cm2 ﬁeld was delivered using an Elekta VersaHDTM linac
(Elekta Corporation, Stockholm, Sweden). The irradiated ﬁlms were
scanned with an Epson Expression 10000XL (Seiko Epson Corporation, Nagano, Japan). Since the attenuation by surrounding Ti casing
was small, the full width a half maximum (FWHM) of the magnetic
disk was measured to determine the dimension of the metallic port
model.
The density of the metallic port was determined by comparing
TPS calculations with IC (31006 PTW Pinpoint Ionization Chamber,
effective volume 0.015 cm3, PTW, Freiburg, Germany) measurements.
The measurement setup is shown in Fig. 2: the isocenter was located
at 15 cm depth and the source-to-surface (SSD) was 85 cm; the

from 7 to 15 cm under the water surface. To conﬁrm if the IC was
exactly aligned with the metallic port for the parallel setup, the location of the metallic port was slightly adjusted laterally until the IC
reading reached the minimum. The measured doses at depths were
compared with dose calculations by collapsed cone convolution (CCC)
algorithm in Pinnacle TPS with a dose grid of 1 9 1 9 1 mm3.
Although there are more accurate dose algorithms 27 that can be used
to reduce metal artifact and calculate dose around high-density
heterogeneities, the CCC algorithm was chosen because it is the
default and also the most accurate dose algorithm used by Pinnacle
and the purpose of this study was to calibrate the Pinnacle TPS to
accurately calculate dose around the metallic port. The density in the
TPS model of the metallic port was adjusted with an extended CT
conversion table in Pinnacle until the calculation results agreed with
the measurements. However, the attenuation from the metallic port
model is determined not only by the density of the model but also the
dimensions (both diameter and thickness) of the model in TPS. For
example, increasing the diameter of the metallic port model in the
TPS will yield more attenuation in the parallel direction [Fig. 2(b)],
while the effect in the perpendicular direction would not be signiﬁcant. Also, increasing the density of the model will yield increased
dose close to the metallic port because of increased scatter, while
doses at deeper points will decrease due to increased attenuation.
Therefore, modeling of the metallic port in the TPS requires ﬁne
adjustments of the combination of density, diameter, and thickness.
In this study, we aimed to ﬁnd the best model that yields the best
agreement between all TPS calculations and measurements. As a
result, the dimension of the metallic port model may be different from
the ﬁlm measurement result.
Contouring the metallic port may have large uncertainties
because of the presence of artifacts induced by the metallic port in
the kilovoltage (kV) CT images, and most patients only have kV CT
images available. In some clinic, part of the artifact is included in the
metallic port contouring which can cause possible dose error. In this
study, we compared our new model with two widely used clinical
models (Fig. 3): in clinical model #1, the titanium shell and magnetic
disk were contoured by the dosimetrist based on the physical dimensions, CT images, and “bone” window/level. The densities of the
Titanium shell and magnetic disk were overridden by their nominal
densities, and surrounding artifacts were overridden as water; in clinical model #2, the metallic port was contoured based on CT images
only with “bone” window/level and some of the artifacts were therefore included. The surrounding artifacts were overridden as water
and the contoured metallic port utilized the assigned default density
converted from the CT number; in our new model, the location of
the disk and its tilted angles in transverse and sagittal plane were
identiﬁed from the CT images using “bone” window/level. The geo-

F I G . 1 . Image of a typical metallic injection port taken out of a
breast tissue expander (ALLERGAN, Santa Barbara, CA).

metrical information of the metallic port, such as the location of the
center of the disk and tilted angles in lateral and sagittal plane on
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(b)
(parallel)

Metallic port
(perpendicular
or parallel)

Solid
Water

5 cm

IC measurement
@ depth = 7~15 cm
Isocenter

Water

Solid
Water

(perpendicular)

F I G . 2 . (a) Schematic illustration of the
ion chamber (IC) measurement setup. The
IC was placed directly under the metallic
port and the distance between the IC and
water surface varied between 7 cm and
15 cm. (b) The metallic port was placed on
a solid water phantom surface with parallel
(top) and perpendicular (bottom) setup.

F I G . 3 . Different metallic port models
used in this study. 2D and 3D images of
each model are shown.

the CT images, was transferred to an in-house MATLAB (Mathworks,

various amount of ﬂuid inside during radiation,6 we simulated both

version 7.9, Natick, MA, USA) code to model the disk three-dimen-

completely deﬂated and inﬂated implant cases to evaluate the accu-

sionally. We then generated the contour of the metallic port using

racy of our model in these two extreme situations. A 6.3-cm water

the in-house code and used the new contour to update the ﬁle con-

equivalent solid block was placed on a wooden lung phantom to sim-

taining the structure set in Pinnacle. The density of the metallic port

ulate a fully inﬂated tissue expander. Under the block, a 1-cm Super-

was overridden by the value determined from IC measurement

ﬂab bolus was place on the lung phantom to simulate the chest wall.

described previously. The surrounding artifacts were overridden as

For a deﬂated tissue expander, a 2-cm block was used to represent

water.

the tissue expander. The whole phantom was scanned by a GE
LightSpeed 16 Slice computed tomography (CT) scanner (GE Health-

2.2 | Validation of the new metallic port model and
two clinical models

care, Little Chalfont, UK) and the CT images with 2.5 mm slice thickness were imported into Pinnacle 9.8 TPS.
Thermoluminescent dosimeters were placed to measure the dose

To validate our model in a more clinically realistic situation, simpli-

around the metallic port as shown in Fig. 4, and the total number of

ﬁed anthropomorphic phantoms were used to simulate a patient

TLDs was 28 (24 plus 1 background and 3 calibration TLDs). The

body. Because different physicians prefer tissue expanders with

SSD was 90.7 cm for inﬂated case and 95 cm for deﬂated case, and

YOON
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F I G . 4 . Schematic illustration of TLD
measurement setup in simpliﬁed
anthropomorphic phantoms simulating (a)
inﬂated and (b) deﬂated tissue expanders
implanted in a patient’s body. Numbers
with circle represent TLD measurement
points.

the distance between metallic port and water surface was 2 cm for

The ﬁtting is usually very good and it has a much smaller variance

both cases. Measurement points 1, 2, and 4 were located 2.5 cm

than the other factors according to Kirby et al.28; the system sensi-

away from the center of the port, and point 3 was directly under

tivity of our TLD reader was well established and the average stan-

the metallic port. A two-ﬁeld open ﬁeld (gantry angles 90° and 270°)

dard error of the mean dose was well within 4%.29

plan with a ﬁeld size of 10 9 10 cm at isocenter, a volumetric2

modulated arc therapy (VMAT) plan (a single 180° arc from 90° to
270°) and a four-ﬁeld IMRT (4ﬂd-IMRT) (gantry angles 70°, 90°,
270°, and 290°) plan were generated for the phantom. For all plans,

2.3 | Comparing the new model with clinical
models for a patient case

the isocenter was located at the interface between lung and chest

To further compare the new model with the clinical models, point

wall and was aligned with the center of the metallic port, as shown

doses and dose–volume histograms (DVHs) were calculated for a

in Fig. 4. For 4ﬂd-IMRT and VMAT plan optimizations, the lung

patient case. A conventional plan containing a pair of opposite tan-

phantom and an imaginary planning target volume (PTV) which

gent beams with wedges, a VMAT plan and a 4ﬂd-IMRT plan were

included the measurement points were contoured in the Pinnacle

tested. The PTV included the chest wall, supraclavicular area, axillary

TPS. A single fraction of 1 Gy was prescribed. TPS calculated point

area, and internal mammary chain area. The dose prescription was

doses based on the new model and two clinical models were com-

50 Gy administered in 25 fractions for all the plans. For the conven-

pared with TLD measurements.

tional plan, a 6 MV open beam with gantry angle 307° together with

After TLD measurements, we performed TLD calibrations by

a 20° wedge, and a 10 MV open beam with gantry angle 127°

sandwiching a TLD packet in solid water phantoms, delivered a

together with a 21° wedge were used. For the VMAT plan, a dual-

known dose to the TLD packet and recorded the TLD reading. This

arc with 220° rotations was used to cover the PTV. The beam geom-

was repeated for several dose levels and a calibration curve was cre-

etry consisted of a 0° couch angle and a 45° collimator angle. The

ated based on the readings. The TLD packets were read using a

4ﬂd-IMRT plan consisted of three 6 MV IMRT beams with gantry

REXON UL-320 Reader (Rexon Components, Inc., Beachwood, OH,

angles of 324°, 304°, and 124°, and one 10 MV IMRT beam with

USA). The TLD heating curve lasts 30 s and contains two plateaus,

gantry angle of 160° to cover the whole PTV. For comparison, a

one 50° and one 240°. Each TLD packet (i.e., measurement point)

baseline condition (no disk) was created with the metallic port and

was ﬁlled with approximate 45 mg of TLD powder. The TLD powder

the tissue expander overridden as water to simulate a homogeneous

in each packet was divided into three samples of approximately

breast without a tissue expander. Doses at two points close to the

15 mg each and the three samples were used to determine the

skin but at depths deeper than 1 cm and doses at two points on the

mean dose and standard deviation of the mean for each TLD packet.

chest wall were calculated (Fig. 5). A “reduced-PTV” was deﬁned for

To minimize daily variation due to decay after irradiation, TLD read-

the DVH evaluation purpose: the original PTV is narrowed down to

ing were actually started after 2 days so that signal fading after irra-

the slices containing the metallic port in the CT images and the tis-

diation could be ignored.

sue expander plus the metallic port were excluded because we were

The possible TLD uncertainties include fading, dose–response

only interested in the dose delivered to the patient’s tissue.

nonlinearity, energy response corrections, and system sensitivity.
Among these uncertainties, the fading effect was basically negligible
because TLD reading were started after 2 days so that signal decay

3 | RESULTS & DISCUSSION

after irradiation could be ignored; energy response corrections were
not necessary because we used the same beam energy for both

The ﬁlm measurement results for parallel and perpendicular setups

measurements and calibrations; the dose–response nonlinearity was

are shown in Fig. 6. It was found that the radiological diameter of

calibrated during TLD calibrations by delivering several known dose

the metallic port was 1.75 cm and the thickness was 2.5 mm, and

levels (the dose range covers the expected measured dose values) to

these were smaller than the nominal diameter (2.1 cm) and thickness

the reference TLDs and doing a linear least-squares ﬁt of the data.

(3.5 mm) that included Ti shell. Ti casing caused a very dim shadow
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in the ﬁlm image. This was expected, since the effective thickness of

metallic port is very thin, the side scatter in water smeared out this

the Ti wall was less than 0.2 g/cm2 (= 4.5 g/cm3 9 0.04 cm), which

dose drop at shallow depth with the parallel setup. However, since

can be ignored without noticeable change in the calculated doses.

the thickness of a typical tissue expander is greater than 2 cm, this

Using the determined dimensions from the ﬁlm measurements,
we found that the calculated doses in the TPS did not match the IC

dose difference would not affect the accuracy of dose calculation
within a patient’s tissue.

measurements with the perpendicular setup when the density was

The calculated and measured doses using the simpliﬁed anthro-

adjusted for the parallel setup measurements. To achieve the best

pomorphic phantoms are shown in Table 1 together with the dis-

agreement for both setups, the thickness and the diameter of the

crepancies

metallic port were decided to be 5 mm and 1.75 cm, and the density

discrepancy was expected at locations where the dose impact of the

of the port was decided to be 7.5 g/cm3. The IC measurements and

metallic port and the limitation of TPS’s capability of handling high

calculated doses are shown in Fig. 7, and they show good agreement

density heterogeneity were manifest. For the inﬂated case, and

(within 1%) for all depths and photon energies except at 2 cm depth

especially for open and 4ﬂd-IMRT plans, dose perturbations caused

with the perpendicular setup where the difference was 4.1% for

by the metallic port were signiﬁcant at points 1 and 2 because both

10 MV photons and 4.7 % for 15 MV photons. This could be attrib-

plans contained beams that were parallel to the port, while points 3

uted to the fact that the radiation beam was signiﬁcantly attenuated

and 4 were relatively further away from the metallic port. This was

by the metallic port with the perpendicular setup, while TPS could

also supported by the fact that the dose discrepancies at points 3

not handle this high density heterogeneity satisfactorily. Because the

and 4 were almost identical for different port models. For VMAT

between

measured

and

calculated

doses.

Large

plans, the dose discrepancies were more uniformly distributed
because of the characteristics of VMAT beams (rotational). The dose
discrepancies between TPS calculations and TLD measurements
were larger when clinical model 1 or 2 was used, while our new
model introduced smaller discrepancies in most cases. For the
deﬂated case, all four points were closer to the metallic port and the
largest discrepancy showed up at different locations for different
models. The dose discrepancies were overall larger than those in the
inﬂated case, especially for clinical model 1 or 2, because less scatter
doses were generated in the smaller volume of water surrounding
the metallic port and these scatter doses could smear out the dose
impact of the metallic port. The new model still provided much better accuracy in most cases. Overall, the TPS calculations based on
the two clinical models showed worse agreement with TLD measurements compared with the new model. For all the measurement
points, TPS calculations based on the new model agreed with TLD
measured doses within 5.0%, which was within the accuracy limit of
F I G . 5 . Photon dose calculation points in a PMRT patient with a
tissue expander. The blue contour represents PTV, and the purple
color wash represents reduced-PTV (PTV minus tissue expander) on
this slice.

TLD. Therefore, the new photon metallic port model was validated
for different beams in the phantoms.
Point doses within the PMRT patient are listed in Table 2. For all
plans and models, the dosimetric impact of the metallic port on chest

F I G . 6 . Projection images of the metallic
port on Gafchromic ﬁlms for (a)
perpendicular and (b) parallel setup.
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F I G . 7 . Depth doses under the metallic
port for (a) perpendicular and (b) parallel
setup for 6, 10, and 15 MV photons with
ﬁeld size of 10 9 10 cm2. (Solid lines) Ion
chamber measurement and (dotted lines)
TPS calculations were plotted on the same
graph. Note the depth here means the
distance between the metallic port and ion
chamber.
T A B L E 1 TLD measurements (mean  standard deviation of the mean) and TPS calculated doses based on different models for open beam,
VMAT, and 4ﬂd-IMRT plans for simpliﬁed anthropomorphic phantoms. TLD measurements were used as the reference for dose difference
calculations. (TE: tissue expander).

TE status

Plan

Inﬂated

Open

VMAT

4ﬂd-IMRT

Deﬂated

Open

VMAT

4ﬂd-IMRT

Point

TLD
Dose (cGy)

Clinical #1
Dose (cGy)

Clinical #2
Difference (%)

Dose (cGy)

New
Difference (%)

Dose (cGy)

Difference (%)

1

94.8  1.4

86.7

8.5

96.5

1.8

94.2

0.6

2

93.6  1.8

88.8

5.2

97.1

3.7

95.9

2.4

3

91.9  1.1

91.4

0.5

91.4

0.5

91.4

0.5

4

92.8  2.7

93.4

0.6

93.4

0.6

93.4

0.6

1

99.9  2.4

97.7

2.2

98.6

1.3

98.8

1.1

2

95.3  0.9

94.0

1.3

96.0

0.8

95.6

0.3

3

91.0  0.9

90.3

0.8

90.7

0.4

90.6

0.5

4

93.7  1.8

90.9

3.0

91.2

2.7

91.3

2.6

1

106.9  0.1

100.2

6.3

102.8

3.9

104.0

2.7

2

104.1  1.0

96.0

7.8

98.0

5.8

99.3

4.6

3

97.2  0.4

99.5

2.4

99.5

2.4

99.5

2.4

4

93.8  1.9

98.5

5.0

98.5

5.0

98.5

5.0

1

95.7  1.8

85.3

10.8

103.5

8.2

93.8

2.0

2

99.1  1.7

89.1

10.0

104.7

5.7

97.6

1.5

3

97.3  2.1

96.1

1.2

103.5

6.4

96.4

0.9

4

96.6  0.8

97.7

1.1

105.3

9.0

98.0

1.4

1

103.8  2.1

98.2

5.4

109.9

5.9

100.4

3.3

2

103.0  2.3

97.8

5.1

108.7

5.5

99.2

3.7

3

96.8  0.6

92.6

4.3

102.4

5.8

95.0

1.8

4

100.7  1.2

94.4

6.2

105.7

5.0

97.8

2.9

1

98.2  3.5

89.3

9.0

104.0

5.9

95.7

2.5

2

99.0  1.7

88.8

10.3

102.1

3.1

95.6

3.4

3

104.0  1.1

100.4

3.4

107.7

3.6

99.9

3.9

4

100.6  2.2

101.2

0.6

108.2

7.6

100.8

0.2

wall was negligible, while the port introduced signiﬁcant dose shad-

the whole PTV DVH because the portion of the volume of the

ows in skin area, especially in the conventional plan. For the VMAT

metallic port in the PTV was small, except VMAT plan in which

and 4ﬂd-IMRT plans, the effect of the metallic port was less signiﬁ-

the DVH curve was shifted to the left with the new model. For the

cant compared with the conventional plan due to the increased

reduced-PTV, the choice of the model has a more pronounced effect

number of beam angles. Compared with the new model, clinical

and the shift of the DVH curves depends on the plan and the mod-

model #1 overestimated the dose attenuation from the metallic port,

els in a complex way. The change in target coverage caused by the

while clinical model #2 underestimated the attenuation.

metallic port was less signiﬁcant than that reported by Chen et al.,18

The DVHs for the PTV and reduced-PTV are shown in Fig. 8.

and it is possibly due to the different models and TPSs used in their

Overall, the choice of the metallic port model has a small impact on

study and ours. Since point dose calculations revealed that the
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T A B L E 2 Calculated doses based on different models for conventional, VMAT, and 4ﬂd-IMRT plans for a PMRT patient. The “no disk” was
used as the reference for dose difference calculations. (CW: chest wall).
Clinical 1

Clinical 2

New

Plan

Point location

No disk
Dose (cGy)

Conventional

CW1

4562.6

4564.9

CW2

4561.8

4566.5

0.10

4563

0.03

4563.1

0.03

skin1

5336.7

4815.8

9.76

5161.4

3.28

4985.8

6.58

skin2

5213.7

4813

7.69

5046.6

3.21

4928.3

5.47

VMAT

4ﬂd-IMRT

Dose (cGy)

Difference (%)
0.05

Dose (cGy)
4563.2

Difference (%)
0.01

Dose (cGy)
4563.5

Difference (%)
0.02

CW1

4972.2

4968.3

0.08

4967

0.10

4951.5

0.42

CW2

4887.8

4872

0.32

4875.8

0.25

4857.4

0.62

skin1

5090.2

5050.3

0.78

5070

0.40

5050.9

0.77

skin2

5250.2

4892.8

6.81

5099.1

2.88

4988.6

4.98

CW1

4972.4

4971.3

0.02

4973.2

0.02

4973.7

0.03

CW2

5021.9

5020.8

0.02

5024

0.04

5024.8

0.06

skin1

5312

4986.7

6.12

5183.5

2.42

5119.4

3.63

skin2

5533.9

5205.9

5.93

5378.7

2.80

5333

3.63

metallic port has a negligible impact on chest wall, the DVHs for

patient, e.g., metal implants within chordoma patients, pacemaker,

organs at risk like lung or heart were not analyzed because they are

hip prosthesis, dental implants, etc.
One of the limitations of this study is that we only investi-

further away from the port than chest wall.
25

gated one type of the tissue expander (McGhan Style 133,

reported an average 7% dose reduction to skin surface in a sample

ALLERGAN, Santa Barbara, CA, USA), while other brands of tissue

of PMRT patients with tissue expanders using opposing tangent

expanders are also used for breast reconstruction,20 and only

beams, and Chatzigiannis et al.17 reported 7% to 13% dose reduc-

modeled the metallic port in one TPS (Pinnacle, Philips Healthcare,

tion with the expander in place for two 6 MV tangential photon

Fitchburg, WI, USA). However, it seems that the tissue expander

beams, and our study showed 5.5%~6.6% dose reduction in the skin

used in this study was the most popular type used in the US and

area for the conventional plan. The dose reduction increased to

other countries according to literature14–17,24,25,31 and Pinnacle is

15.6%~15.8% when we only used one beam in the conventional

one of the most widely used TPS worldwide, which means our

16

plan, which is close to 22% reduction reported by Damast et al.

model is applicable to most clinics. The methodology used in this

for a single 6 MV beam.

study is generally applicable and clinics that use different brands

Our results are consistent with previous studies. Gee et al.

The strength of this study is that a generic and simpliﬁed model

of tissue expanders or TPS could create their own model and

of the metallic port for all possible conditions was developed and

improve their dosimetric accuracy by using our approach. Second,

validated. Because of the simple geometry, the contours of the

only one patient’s plans were used for clinical evaluations. As we

model can be reproduced easily or be stored as a template in Pinna-

mentioned in the introduction section, our goal is to model the

cle. The model can be used for any photon treatment and a short

metallic port and we already validated and compared the new

script in Pinnacle can be used to add the metallic port contour to

model with the clinical models using simpliﬁed anthropomorphic

patients’ plans automatically. The only things that need to be

phantoms. The patient case was used as an example to further

adjusted in the script for a speciﬁc patient are the center position

demonstrate the necessity of using our new model to calculate

and the orientation of the model which can be quantiﬁed by check-

doses and to show the dose perturbation depends on the plan

ing the planning CT images. The density of the metallic port should

and the models.

be overridden by the value determined in this study (7.5 g/cm3), and
the surrounding artifacts should be overridden as water. Our
research will allow TPS to accurately calculate dose distribution sur-

4 | CONCLUSIONS

rounding the metallic port. Without this information, clinicians may
ignore the dose perturbation or prescribe an inaccurate amount of

We have modeled the metallic port within the tissue expanders in a

additional dose to compensate for the miscalculated dose shadow,

commercial TPS based on radiological measurements. Calculation

which may either cause the loss of target coverage or increase the

results from the new model agreed with IC measurements within 1%

risk of complications like capsular contracture since radiation to the

for most cases. Using simpliﬁed anthropomorphic phantoms, the TPS

breast after reconstruction can signiﬁcantly increase the rates of

calculated point doses based on the new model agreed with TLD

10,30

The methodology utilized in this study can

measurements within 5.0% and showed better accuracy than dose

also be used to investigate other high-density materials within the

calculated based on the clinical models. For a PMRT patient case,

these complications.
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(a)

(b)

Conventional PTV

100%
90%

Conventional reduced-PTV

90%

Clinical1
Clinical2
New
NoDisk

80%
70%
Volume (%)

70%
Volume (%)

100%

Clinical1
Clinical2
New
NoDisk

80%
60%
50%
40%

60%
50%
40%

30%

30%

20%

20%

10%

10%

0%

0%

4600

4800

5000

5200

5400

5600

4600

4800

5000

Dose (cGy)

5400

5600

(d)

VMAT PTV

100%
90%

90%

60%

Clinical1
Clinical2
New
NoDisk

80%
70%
Volume (%)

70%

VMAT reduced-PTV

100%

Clinical1
Clinical2
New
NoDisk

80%
Volume (%)

5200

Dose (cGy)

(c)

50%
40%

60%
50%
40%

30%

30%

20%

20%

10%

10%
0%

0%
4600

4800

5000

5200

4600

5400

90%

100%

60%

Clinical1
Clinical2
New
NoDisk

70%

50%
40%

60%
50%
40%

30%

30%

20%

20%

10%

10%

0%

0%

4600

4800

5000

5200

5400

4600

Dose (cGy)
FIG. 8.

5400

4-fld IMRT reduced-PTV

80%
Volume (%)

70%

5200

90%

Clinical1
Clinical2
New
NoDisk

80%

5000

(f)

4-fld IMRT PTV

100%

4800

Dose (cGy)

Dose (cGy)

(e)

Volume (%)
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4800

5000

5200

5400

Dose (cGy)

DVHs for PTV and reduced-PTV for (a–b) conventional, (c–d) VMAT, and (e–f) 4ﬂd-IMRT plans for a patient case.

we found that the metallic port has a negligible dosimetric impact on

local dose to the patient. Therefore, using our model in treatment

chest wall, while the port introduced signiﬁcant dose shadows in

planning could improve the accuracy of dose delivery for PMRT

skin area. The current clinical port models overestimate or underesti-

patients who have temporary tissue expanders implanted during

mate the dose perturbation, and as a result, may deliver unexpected

radiotherapy.
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